Category: News

Poster Presented on “A Muti-centric placebo-controlled double-blind clinical study to determine the efficacy of a novel fenugreek seed (Trigonella foenum-graecum, FENFURO) extract in patients with Type-2 diabtes: an add-on study at Diabetes UK Professional Conference, Glasgow, UK on 2-4 March 2016.

Team Furocyst had conducted the CME conference of Obs./Gyn. doctors- Mohali Chapter on 6th January, 2016 at Hotel Cama, Mohali.
Speaker Dr Vinnet Nagpal, Sr consultant at Civil Hospital, mohali made emphatic remarks on study results of Furocyst & suggested to
prescibed as alternate nutritional/dietary supplement option to pcos patients.

Abstract has been accepted as a poster presentation- ‘Clinical evaluation of fenugreek seed extract (Fenfuro) in patients with type-2 diabetes: an add-on study in 154 patients’ at the 43rd annual conference of Research Society for the Study of Diabetes in India – RSSDI 2015 at Lucknow, UP (30th, 31st October & 1st November 2015).

Over 30 lakh diabetes patients across the country were on pioglitazone drug banned last week City doctors are receiving anxious calls from diabetic patients worried about ban on anti-diabetic drug pioglitazone. “Pioglitazone is a good drug. The only issue is that it should be used with certain restrictions,” said Dr KP Singh, senior consultant, endocrinology, Fortis Hospital, SAS Nagar. He said, “It is an affordable drug, which is at least 10 times cheaper as compared to other medicines. So we were prescribing it commonly.” Following the ban, now Dr Singh is getting 30-40 queries every day from his patients regarding the medicine. The medicine, Dr Singh said, should not be used for patients suffering from urinary bladder cancer, heart problems, kidney failure. “The patients can now either switch to insulin or opt for costlier yet less effective drugs,” Dr Singh said. According to experts, Pioglitazone is the second and third line of treatment for Type 2 diabetes. According to data available, over 30-lakh diabetes patients across the country were on pioglitazone drug banned last week. The union health ministry had issued a notification announcing the ban on June 18. Along with pioglitazone, two other drugs – analgin (painkiller) and deanxit (anti-depressant) – were also banned due to alleged health risks associated with the drugs. Doctors complained that the Indian government relied on foreign data which links urinary bladder cancer with the intake of pioglitazone. Some doctors allege that scientific evidence was ignored before banning the drug and that its benefits outweigh the risk factors. However, Dr RJ Dash, considered a pioneer in endocrinology in the country, believes that it was a right decision to ban the medicine. “When it is established that there are serious side effects of the medicine then there is no question of continuing the sale of medicine,” he said. He added that some physicians were using this medicine mindlessly without knowing its side effects, so it was right to stop the sale of this medicine. Ref: HT live Chandigarh- Tuesday, July 9,2013

Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity & General Health.

We are glad to inform that our company has been awarded ‘Asia Pacific Most Promising Enterpreneurship Award.’

Diabetes is a progressive disease; therefore, a single treatment regimen cannot be followed for long. Also it is a complex disease with genetic predisposition; hence, a single therapeutic regimen is not applicable in all cases.  The prevalence of diabetes has reached epidemic proportions, resulting in an enormous increase in the need for dialysis and coronary artery bypass grafts. Treatments are also needed for eye disease ,neuropathy, sexual dysfunction depression and leg ulcers. According to the international Diabetes Federation (IDF), in 2011, the number of persons suffering from diabetes in india was 61.3 million and is estimated to reach 101.2 million by 2030. Diabetes is a complex metabolic disorder, with a multitude of components, one of which is the elevation or excursion in blood sugar .The complexity of the disease urgently requires technological interventions to be a part of day to day management in the absence of which the therapy fails, as is happening with more than 80 % of patients on conventional diabetes treatment.  After the publication of the Diabetes Control and Complications Trial (DCCT) with type 1 diabetes , and the United Kingdom Prospective Diabetes Study (UKPDS) with type 2 diabetes, the management of diabetes has radically changed in the past decade. Now, self –monitoring of blood glucose (SMBG) with a glucometer , has become indispensable, whatever may be the type and stage of the illness. Technology in diabetes is linked to blood glucose monitoring and delivery devices. Blood Glucose monitors and insulin pens have been popular for years. Continuous glucose monitoring (CGM) and insulin pump therapy are being incorporated gradually and systematically into routine diabetes therapy. The idea behind incorporating technology in diabetes care is to ensure success in maintaining healthy levels of HbA1c,blood pressure and LDL cholesterol thereby , preventing the onset of micro and macro vascular complications of diabetes.  Diabetes is a progressive disease therefore a single treatment regimen cannot be followed for long Also, it is a complex disease with genetic predisposition hence , a single therapeutic regimen is not applicable in all cases.CGM replaces the pricking of a finger tip to get a drop of blood , which is used ia a glucometer to measure the blood glucose with a stand alone tiny sensor needle with measures up to 288 blood glucose values over a period of 24 hours and can be situ from three days to three weeks. This device can be used as a blindor a real time device where the patient will be able to see the change in the blood glucose trends, the lows the highs , the excursions, the trend during sleep etc, This is the first in a series of columns that will deal with technological innovations in diabetes.  Source: DOC N DOC, February 2012 by Jothydev Kesavadev, MD

Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity, PCOS(ploycystic ovarian syndrome) & General Health.

TEAM FENFURO had participated in UPDACON-annual congress of Uttar Pradesh Diabetes Association which was held on 17 & 18 November 2012 at Scientific Convention Center, CSMMU ,Lucknow, the state capital of Uttar Pradesh which happens to be highest populated state of India.  The conference was attended by more than 600 physicians and endocrinologists who put their idea to fight with Diabetes and create awareness among people for the prevention of diabetes and they have also promoted life style modifications as well as motivated people for early detection and treatment and to avoid late life threatening complications of Diabetes. It was the endeavor to update physicians and general practitioners about newer modalities of diagnosis and treatment.

Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity, PCOS(ploycystic ovarian syndrome) & General Health.

We are glad to inform that our Company has been awarded SME BUSINESS EXCELLENCE AWARD,2014

TEAM FENFURO participated in BPCON 2013 – 23rd annual meeting of Indian society for Hypertension held at scientific convention center of King George’s Medical University Lucknow, Uttar Pradesh from 16th to 17th November 2013.

Around 20 international and 20 national faculty of repute came together to bridge the gap of research and clinic and it was attended by approximately 1000 physicians, diabetologist and cardiologists of our country.

TEAM FENFURO particpated in 32nd Edition of India International Trade Fair (IITF) held at Pragati Maidan from November 14th to 27th, 2012. IITF is the largest trade fair in this part of the world. This year the theme was “Skilling India”